View Older Stories View More Recent Stories
-
Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer
-
The Center for Breakthrough Medicines is Building the World's Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) to Launch in King of Prussia, PA
-
/C O R R E C T I O N -- The Discovery Labs/
-
SHINE year-end report highlights construction progress, strong investor confidence
-
Vesta Healthcare Announces $30 Million Series A Led by Oak HC/FT and Deerfield to Engage and Support Caregivers
-
Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference
-
R&D Alliance Between Harvard and Deerfield Announces First Project Agreement
-
Nuvo Pharmaceuticals™ Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty
-
Yeda, the Commercial Arm of the Weizmann Institute of Science, and Deerfield Create Orchard Innovations, LLC
-
Duke University and Deerfield Management Announce Four Points Innovation
-
Conventus Orthopaedics Acquires Novel Intramedullary Technology from IntraFuse
-
Zafgen (ZFGN) and Chondrial Therapeutics Report Merger Agreement
-
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
-
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
-
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development
-
Black Diamond Therapeutics Closes $85 Million Series C Financing
-
Civetta Therapeutics Announces $53 million Series A to Advance Lead Programs and Develop Proprietary Platform Targeting Propeller Proteins
-
Quartet and Cambia Health Solutions Regional Health Plans Team up to Bring Improved Access to Mental Health Care Across the Pacific Northwest
-
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
-
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2019 Financial Results
-
Form 13F-HR DEERFIELD MANAGEMENT For: Sep 30
-
Form 4 AdaptHealth Corp. For: Nov 08 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Chemical & Engineering News Names Frontier Medicines One of its 10 Chemistry Start-Ups to Watch
-
DFB Healthcare Acquisitions Corp. Announces Closing of Business Combination With AdaptHealth Holdings LLC
-
DFB Healthcare Acquisitions Corp. Announces Stockholder Approval of Business Combination With AdaptHealth Holdings, LLC
-
Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting
-
Donald A. Deieso, Ph.D., WCG (WIRB-Copernicus Group), Lewis C. Cantley, Ph.D., Weill Cornell Medicine & NewYork-Presbyterian Hospital, And Vanessa Bayer, Actress, Writer And Comedian, To Be Honore
-
DFB Healthcare Acquisitions Corp. and AdaptHealth Holdings LLC Announce Amendments to Merger and Subscription Agreements
-
DFB Healthcare Acquisitions Corp. Announces Record Date for Special Meeting of Shareholders
-
SHINE closes $50-million financing with Oaktree to support execution of construction and commercialization plans
-
NewLink Genetics (NLNK) and Lumos Pharma Enter Merger Agreement
-
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
-
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
-
MATTER to Open in New York City as Part of New Life Sciences Campus
-
Deerfield Management Brings Together Scientists, Entrepreneurs and Leading Companies to Form the New York-Based Healthcare Innovation Campus
-
NYCEDC and Deerfield Management Partner to Create a Life Sciences Campus -- MATTER to Create LifeSci NYC's Newest Incubator
-
Nkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019
-
FierceBiotech names Frontier Medicines one of its "Fierce 15" biotech companies of 2019
-
Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer
-
Edgewise Therapeutics Closes $50 Million Series B Financing
-
Nkarta Therapeutics Appoints Vice President of Regulatory Affairs
-
KemPharm (KMPH) Enters Definitive Collaboration and License Agreement for its ADHD Candidates with Affiliate of Gurnet Point Capital
-
KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital
-
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials
-
Oncorus Announces $79.5 Million Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors
-
Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Nuvo Pharmaceuticals™ Announces 2019 Second Quarter Results
-
Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies
-
Nuvo Pharmaceuticals™ Provides VIMOVO Patent Update

